ABSTRACT
OBJECTIVE: Approach to the pharmacodynamics of cisatracurium in newborn. METHODS: Sixty patients were randomized to two groups: Group Ⅰ and Group Ⅱ , received( iv) 2ED95 or 3ED95 cisatracurium in 5 seconds respectively, n=30. Neuromuscular transmission was monitored and Intubation conditions were assessed at 120s after cisatracurium administration using a 4- part scale. Observe onset time, TOF no reaction period, duration of action, recovery index, duration in vivo. RESULTS: The muscular blockage and conditions of intubation after 120s were different between two groups( P0. 05) . CONCLUSIONS: 3ED95 cisatracurium produces quicker, safer onset time and acceptable intubating conditions in the great majority of newborn than 2ED95. The TOF no reaction period, duration of action and duration in vivo were longer in 3ED95 group than in 2ED95 group, but recovery index are no significant between 2 groups with dosage.